Skip to main content

M16-066 A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16

NCT03398135

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

AbbVie

The purpose of this study is to evaluate the efficacy and safety of Risankizumab versus placebo and determine how well it works as maintenance therapy and long-term therapy for subjects with moderate to severe ulcerative colitis who completed their participation in study M16-067.

This study is currently enrolling.